From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We?

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|22|42|6426-6433

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.22, Iss.42, 2017-01, pp. : 6426-6433

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cannabis in the Arm: What Can we Learn from Intravenous Cannabinoid Studies?

By  

Current Pharmaceutical Design, Vol. 18, Iss. 32, 2012-11 ,pp. : 4906-4914

Bentham Science Publishers

Access to resources Recommend Favorite

Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 6, 2014-08 ,pp. : 953-960

Bentham Science Publishers

Access to resources Recommend Favorite

Personalized medicine in oncology: where have we come from and where are we going?

By André Fabrice   Ciccolini Joseph   Spano Jean-Philippe   Penault-Llorca Frédérique   Mounier Nicolas   Freyer Gilles   Blay Jean-Yves   Milano Gérard  

Pharmacogenomics, Vol. 14, Iss. 8, 2013-06 ,pp. : 931-939

Future Medicine

Access to resources Recommend Favorite

COX-2 controversy: where are we and where do we go from here?

By Khanna Dinesh  

Inflammopharmacology, Vol. 13, Iss. 4, 2005-09 ,pp. : 395-402

VSP

Access to resources Recommend Favorite

Paediatric Pharmacy in Australia: Where Have We Come From and Where Do We Need To Go?

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 43, Iss. 1, 2013-03 ,pp. : 45-48

John Wiley & Sons Inc

Access to resources Recommend Favorite